Logo

The European Commission Approves GSK’s Omjjara (momelotinib) for the Treatment of Severe Anaemia

Share this

The European Commission Approves GSK’s Omjjara (momelotinib) for the Treatment of Severe Anaemia

Shots:

  • The marketing authorisation was granted based on two P-III pivotal clinical trials evaluating the safety & efficacy of Omjjara vs danazol in (MOMENTUM) & vs ruxolitinib in the (SIMPLIFY-1) trial as a treatment of myelofibrosis patients (n=195 & 432)
  • The (MOMENTUM) trial met both the 1EP & 2EP depicting a total symptom score reduction of ≥50% & 25% (momelotinib) vs 9% (danazol) whereas the (SIMPLIFY-1) study showed a reduction in spleen volume by ≥35% & 31% (momelotinib) vs 33% (ruxolitinib)
  • Omjjara (momelotinib) is a JAK1/JAK2 & ACVR1 inhibitor approved for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis

Ref: GSK Image: GSK

Related News:- GSK Receives the US FDA’s Approval of Ojjaara (momelotinib) for Myelofibrosis Patients with Anemia

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions